Star Therapeutics

South San Francisco biotech building best-in-disease therapies; led by Sanofi Ventures and Viking in a 2025 Series D, then a $200M private financing in 2026.

View on the globe

$325MEquity raised in 2025–20262025 $125M · 2026 $200M · 2 equity rounds
$325MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed

Rounds over time log-scaled amounts

Funding history: 2 rounds from Sep 2025 to 23 Oct 2026, $325M equity disclosed. Earlier rounds exist but are not sourced.Sep 2025: Series D financing, $125M; 23 Oct 2026: Private financing, $200M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yet← earlier rounds not sourcedQ42026Q2Q3Q42027Equity round23 Oct 2026 · Private financing · $200M · led by OrbiMed, Janus Henderson InvestorsSep 2025 · Series D financing · $125M · led by Sanofi, Viking Global InvestorsOther · $200MSeries D · $125M
Funding history: 2 rounds from Sep 2025 to 23 Oct 2026, $325M equity disclosed. Earlier rounds exist but are not sourced.Sep 2025: Series D financing, $125M; 23 Oct 2026: Private financing, $200M$10M$30M$100M$300M$1BEarlier rounds exist but are not sourced yetearlier rounds not sourcedQ42026Q2Q3Q42027Equity round23 Oct 2026 · Private financing · $200M · led by OrbiMed, Janus Henderson InvestorsSep 2025 · Series D financing · $125M · led by Sanofi, Viking Global Investors$200M$125M

Funding history 2 rounds · 4 sources · newest first

Earlier rounds not yet sourced. Star Therapeutics raised before Sep 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.

  1. Private financing
    Amount$200M
    Post-money—
    ✓ Confirmed
    Lead
    OrbiMed, Janus Henderson Investors
    Also
    Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital
    Note
    Announced as a 'private financing' with no series name; recorded as stage other. Co-led by OrbiMed and Janus Henderson per the company release. Valuation not stated. Sub-syndicate list is from the release. Trade press dates differ (Oct 22-26) in search snippets only; the release is dated Oct 23.
    Sources
  2. Series D financing
    Amount$125M
    Post-money—
    ✓ Confirmed
    Lead
    Sanofi, Viking Global Investors
    Also
    Janus Henderson Investors, Frazier Life Sciences, GordonMD Global Investments
    Note
    Two secondary sources agree on the $125M Series D and its co-leads: Pharmaceutical Technology (1 Oct 2025, 'raising $125m', jointly headed by Viking Global Investors and Sanofi Ventures) and a Crunchbase News weekly (3 Oct 2025). Month precision used: the company release (BusinessWire, dated 29/30 Sep 2025 per a search snippet) could not be fetched (HTTP 403). Sanofi Ventures PDF not readable and not cited. No valuation stated.
    Sources
  3. Earlier rounds not yet sourced

Investors 15

  • Janus Henderson Investors2
  • OrbiMed1
  • Sanofi1
  • Viking Global Investors1
  • Agent Capital
  • Catalio Capital Management
  • Cormorant Asset Management
  • Frazier Life Sciences
  • GordonMD Global Investments
  • New Leaf Venture Partners
  • NYBC Ventures
  • RA Capital Management
  • Redmile
  • Sofinnova Investments
  • Soleus Capital

Highlighted investors led at least one equity round; the number is equity rounds taken part in.

Related companies shared investors

Also in the South San Francisco hub see on the globe

Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Star Therapeutics and its logo are trademarks of their owners, used here for identification only.